Bellicum Pharmaceuticals, Inc. Forecasted to Earn FY2020 Earnings of ($1.16) Per Share (BLCM)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Jefferies Group issued their FY2020 earnings per share estimates for Bellicum Pharmaceuticals in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Amin anticipates that the biopharmaceutical company will post earnings of ($1.16) per share for the year. Jefferies Group has a “Buy” rating and a $16.00 price objective on the stock. Jefferies Group also issued estimates for Bellicum Pharmaceuticals’ FY2021 earnings at ($0.09) EPS.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.03. The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.03 million. Bellicum Pharmaceuticals had a negative return on equity of 83.23% and a negative net margin of 18,596.03%. The company’s revenue for the quarter was up 18.2% on a year-over-year basis. During the same period last year, the business posted ($0.66) EPS.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 18th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $26.20.

Bellicum Pharmaceuticals (BLCM) traded up $0.17 during mid-day trading on Monday, hitting $8.73. The stock has a market cap of $290.07 and a PE ratio of -2.92. Bellicum Pharmaceuticals has a twelve month low of $7.41 and a twelve month high of $15.55. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08.

A number of large investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in Bellicum Pharmaceuticals by 1.8% during the second quarter. Principal Financial Group Inc. now owns 84,820 shares of the biopharmaceutical company’s stock valued at $991,000 after acquiring an additional 1,482 shares during the period. ProShare Advisors LLC raised its holdings in Bellicum Pharmaceuticals by 14.9% during the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 2,513 shares during the period. Nationwide Fund Advisors raised its holdings in Bellicum Pharmaceuticals by 30.4% during the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Bellicum Pharmaceuticals by 5.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 73,666 shares of the biopharmaceutical company’s stock valued at $910,000 after acquiring an additional 4,104 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Bellicum Pharmaceuticals by 26.6% during the second quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 4,684 shares during the period. 55.28% of the stock is currently owned by institutional investors and hedge funds.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the sale, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. 18.77% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Bellicum Pharmaceuticals, Inc. Forecasted to Earn FY2020 Earnings of ($1.16) Per Share (BLCM)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/25/bellicum-pharmaceuticals-inc-forecasted-to-earn-fy2020-earnings-of-1-16-per-share-blcm.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit